Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has ...
Scientists have discovered a previously unknown mechanism for how aggressive brain cancers reprogram immune system cells from fighting cancer to enabling further tumor growth. The lab of Filippo ...
Wistar Dr. Filippo Veglia's research focus is the molecular and metabolic perturbations that drive the reprogramming of myeloid cells in the brain tumor microenvironment. The lab of Filippo Veglia, Ph ...
The lab of Filippo Veglia, Ph.D., at The Wistar Institute has discovered a previously unknown mechanism for how aggressive brain cancers reprogram immune system cells from fighting cancer to enabling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results